Another study found that ARID1A deficient cells have low antioxidant glutathione (GSH) levels and lower SLC7A11 (cysteine transporter required by GSH) expression making them vulnerable to GSH and glutamate-cysteine ligase synthetase catalytic subunit (GCLC) inhibition and possible cancer treatment through increased ROS formation [75]. Here, ARID1A is linked to cancer.